Abstract
177Lu-DOTAGA-(l-y)fk(Sub-KuE) (177Lu-PSMA I&T) is currently used for
radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC)
in several centers in Europe. It was launched in Tallinn, Estonia, in December 2018. As
an additional project, a model of dosimetric analysis was created, utilizing voxel-based
dosimetry and intra-lesion radiomics to assess their practicality in routine dosimetry
[1]. This was a successful project, and the work is summarized in this chapter.
Keywords: 177Lu isotope, Dosimetry, Positron emission tomography, Prostate cancer, PSMA, Quantitative SPECT, Radiomics, Radionuclide therapy, Voxelbased dosimetry.
Related Books
Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine
Cancer Metastasis and Cancer Stem Cell/Niche
Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature
Controversies in Neuro-Oncology
Current Advances in Breast Cancer Research: A Molecular Approach
Cutting Edge Therapies for Cancer in the 21st Century
Frontiers in Cancer Immunology
Frontiers in Cancer Immunology
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Frontiers in Clinical Drug Research - Anti-Cancer Agents